{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-099645","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.341495+00:00","generated_at":"2026-05-29T23:30:53.964117+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Oruka shareholders approve Series A conversion and adjournment proposals","bullets":["30,598,476 shares voted for Series A conversion; 6,026 against; 1,089 abstaining; no broker non-votes.","29,294,720 shares voted for adjournment proposal; 1,309,805 against; 1,066 abstaining.","Both proposals approved at special meeting held November 14, 2024.","Conversion involves Series A Non-Voting Convertible Preferred Stock issued September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-099645","json":"https://secwatch.observer/filing/0001213900-24-099645.json","markdown":"https://secwatch.observer/filing/0001213900-24-099645.md","text":"https://secwatch.observer/filing/0001213900-24-099645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/0001213900-24-099645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/ea0221692-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:30:53.964117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}